Tandem Diabetes Care Inc (TNDM) Stock AnalysisTNDMTandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tandem Diabetes Care Inc is a good buy right now at a current price of $17.43, especially considering the recent 5-day change of +7.33% and a solid gross margin of 56.11%. The stock has shown resilience with a recent upward trend and positive analyst sentiment, particularly from Canaccord, which sees potential for growth driven by new product launches. However, the main risk is the forward P/E of 117.65, indicating high expectations that may not be met if performance falters.

7 analysts cover TNDM: 1 rate it Buy, 5 Hold and 1 Sell. The average price target is 26.33.